Business

Bottom line

ConvaTec is a chronic-care consumables compounder masquerading as medtech — four franchises (Advanced Wound Care, Ostomy Care, Continence Care, Infusion Care) sharing one polymer-and-adhesive science platform, one global salesforce, one regulatory engine, and one home-delivery channel. The economic engine is a recurring consumables installed base (>90% reorder rates) earning 56% gross margin; the strategic prize is the 400 bps adjusted-operating-margin gap to Coloplast — closing it would unlock $90–100M of incremental profit at unchanged revenue. The market is most likely over-discounting a one-time InnovaMatrix LCD reset (about 2% of group revenue, already impaired) and under-pricing the operating-leverage flywheel that turns each $1 of incremental sales into $0.30+ of incremental adjusted operating profit at the FY2027+ mid-20s margin target.

How This Business Actually Works

This is a consumables-on-an-installed-base business with a polymer cost stack — once a patient becomes an ileostomate, an insulin-pump user, or a chronic-wound case, they reorder pouches, dressings, catheters, or infusion sets every 1–3 days for life, and the manufacturer captures profit only by being clinically preferred and logistically reachable.

The four franchises share one engine, not four

The mix matters less than most analysts treat it. The franchises overlap on adhesives, hydrocolloids, silicones, polymer extrusion, and clinical evidence generation — all four require skin-contact polymers manufactured at very high volumes with FDA/MDR-grade quality systems, and three of the four sell through the same wound/stoma-nurse specifier channel. The synergy is real enough that the group's R&D ($111M in FY2025) is run as one platform, and pilot manufacturing lines validated for one franchise routinely transfer to another.

Takeaway: AWC and Ostomy together are 60% of revenue but only mid-single-digit growth. Infusion Care is 18% of revenue growing at low-double-digits and capacity-led — it punches well above its weight on incremental profit and capex.

Where the dollar actually goes

Cost of goods is dominated by raw materials, not labor or fixed plant. Per CFO disclosure at the 2026 CMD, COGS is roughly 40% of sales; raw materials are 45% of that COGS, overheads 30% (freight 5%, utilities 2%), and the rest is direct labor and depreciation. This is why tariffs and oil prices flow straight to gross margin (~$2–3M per incremental point of inflation in FY2026, doubling to $7–8M in FY2027 as hedges roll off). The mid-20s margin ambition is therefore won below the gross line.

The bottleneck on incremental profit is SG&A and G&A simplification, not gross margin. ConvaTec brought G&A from 13% of sales in 2021 to 6.8% in FY2025 by consolidating CRM systems, centralising procurement, and standing up a Convatec Business Services hub. Each 100 bps of SG&A leverage on a $2.44B base is roughly $24M of operating profit, equal to about 12% of FY2025 GAAP operating income — that is why management's 22.3% → mid-20s glidepath is the single most important number in the model.

What truly drives incremental profit

The Playing Field

The peer set is structurally heterogeneous: only Coloplast is a clean economic substitute, two listed peers (SOLV, SNN) are larger but more diversified, one (PODD) is the demand-side disruptor of Infusion Care, and one (IART) is a wound-recon biologics adjacency in distress. Three of the most relevant competitors — Mölnlycke, Hollister, B. Braun — are private and never appear in any peer screen. Read the listed peer comp for direction, not as the actual playing field.

Takeaway: the listed peer set splits into three economic archetypes. Coloplast is the structural benchmark (high margin, modest growth) ConvaTec is trying to converge on. Insulet is the high-growth disruptor that defines the Infusion Care risk. Solventum and Smith+Nephew are diversified medsurg comparables — informative on margin shape, less on growth dynamics. The five-peer set understates actual competitive intensity because Mölnlycke, Hollister, and B. Braun are private but first-rank in wound, ostomy, and continence respectively.

What the peer set reveals

The instructive divergence is between CTEC and Coloplast. Both sell single-use chronic-care consumables; Coloplast skews more to ostomy/continence (~70% of mix) where pricing is anchored by patient-stickiness, ConvaTec carries roughly a third of revenue in Advanced Wound Care where SOLV/S&N/Mölnlycke pressure prices and CMS LCDs reset whole sub-categories. The 12-percentage-point gross-margin gap (56% vs 68%) is mostly mix and partly scale — closing it is hard. The 4-percentage-point operating-margin gap is cost — closing it is mostly within management's control and is exactly what FISBE+Accelerate is engineered to do.

The other lesson is Insulet's growth profile (24% organic, 34% ROIC). PODD doesn't compete with ConvaTec on the same SKUs — it competes for the patient. Every patient who picks tubeless Omnipod over a Tandem/Medtronic tubed pump is a patient who never buys a ConvaTec infusion set. The mitigant is that the tubed-pump installed base is still growing in absolute terms (Parkinson's, high-dose biologics, GLP-1-extended diabetics), and ConvaTec's own contracted capacity build-out is underwritten by long-term customer agreements. The risk is that the share-of-new-pump-starts curve flattens out the absolute growth in 5–7 years.

Is This Business Cyclical?

Demand is not cyclical; pricing and reimbursement are. Patients with stomas, chronic wounds, neurogenic bladders, and insulin pumps reorder consumables through every recession; the global wound, ostomy, and continence markets all grew through 2008–09 and 2020. What flexes the P&L is regulatory and reimbursement change — a single CMS LCD or a UK NHS tender cycle can reset a whole sub-category overnight.

The chart shows what's distinctive about this industry: the 2019 trough was operational (own goal), not macro. COVID-19 in 2020 actually helped ConvaTec because Advanced Wound Care and Infusion Care volumes held while peers with elective-orthopaedic exposure (SNN) suffered. The 2022 dip was raw-material inflation passing through gross margin, not demand. The single biggest cycle event in the recent dataset is the InnovaMatrix CMS LCD reset (January 2026) — an 80% price cut on one acquired biologic that erases about 2% of group revenue and triggered a $72M non-cash impairment.

The Metrics That Actually Matter

Generic ratios miss this business. Margin trajectory and new-product vitality drive valuation; revenue growth alone does not. The five metrics below explain ~80% of the variance in chronic-care consumables stocks across a cycle.

Takeaway: every metric is pointing in the same direction. The sceptic should focus on whether adjusted vs reported margin definitions hide stock-based compensation or restructuring (the Forensic tab digs into this) — but the underlying compounding is broad-based and visible across multiple operating measures, not a single accounting trick.

The two metrics that should trigger the most scrutiny:

• Adjusted vs GAAP margin gap. FY2025 adj op margin 22.3% vs GAAP 13.0% — a 930 bps wedge driven by amortisation of acquired intangibles ($90M+/year), restructuring, and SBC. This is wider than Coloplast's ~80 bps wedge. The convergence of GAAP toward adjusted is the second-derivative tell on whether margin progress is real.
• InnovaMatrix-adjusted growth. Reported organic 6.6% in FY2025 vs ex-InnovaMatrix 6.4% — these track because InnovaMatrix is small, but the market obsesses about the headline. After 2026 the metric simplifies because InnovaMatrix shrinks to ~$20M of revenue.

What Is This Business Worth?

Best valued as one economic engine, not a sum-of-the-parts. The four franchises share polymer-and-adhesive science, salesforce, regulatory infrastructure, manufacturing (5 plants), and the Convatec Business Services hub; pulling them apart would destroy real synergies, and the management team allocates capital on a single P&L. Treat ConvaTec as a single chronic-care consumables compounder valued on earnings power × reinvestment runway × multiple convergence to Coloplast.

The valuation is not a SOTP. The four franchises are not separately listed, do not have separately measurable assets, share R&D and salesforce, and would not change hands for materially different multiples in a private transaction. InnovaMatrix is the only piece with separable economics, and management has already impaired it 20% — anyone who tries to value ConvaTec as Ostomy + Wound + Continence + Infusion ends up double-counting central costs and missing the polymer/adhesive synergy that is the actual moat.

The valuation is sensitive to one large step-function: if ConvaTec converges to a 25% adjusted operating margin while holding 6–8% organic growth, the business produces about $738M of adjusted operating profit at the FY28 base case (vs $544M actual at 22.3% × $2.44B in FY25). At a Coloplast-style multiple that is a different equity story than what consensus appears to model. Conversely, if margin stalls at 23% and Infusion Care growth halves to mid-single-digits, the cumulative compounding case unwinds and the multiple would likely sit closer to SNN.

Takeaway: the spread from bear to bull on FY2028 adjusted operating profit is roughly $213M — about 27% of base-case earnings power. That is the band the investor should underwrite, not a point estimate.

What I'd Tell a Young Analyst

Five things to watch and one heuristic to ignore.

The single most important habit when reading ConvaTec results is to strip out InnovaMatrix and look at the rest. The four franchises are doing what they were supposed to do; the noise is concentrated in one acquired biologic where the regulator just reset price by 80%. A reader who treats the stripped result as the real business will read the company correctly; a reader who fixates on the headline will mistime entry and exit.